The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | Novel targets for NSCLC
Marina Garassino, MD, University of Chicago, Chicago, IL, talks on uncommon targets for the treatment of non-small cell lung cancer (NSCLC). Dr Garassino discusses how, whilst many novel targets have been identified, such as ROS1, BRAF, HER2 or MET, these are only present in a small number of patients with NSCLC. Dr Garassino also outlines challenges associated with not all centers being able to perform next-generation sequencing (NGS). This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
Disclosures
Marina Garassino has received personal fees or grants from AstraZeneca, MSD, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Inivata, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, Mirati Therapeutics, Daiichi Sankyo, Bayer, GlaxoSmithKline S.p.A, Sanofi-Aventis,, Blueprint Medicine, Janssen and Regeneron Pharmaceuticals; and has received institutional fees or grants from Eli Lilly, Pfizer, AstraZeneca, MSD, BMS, Celgene, Incyte, MedImmune, Novartis, Pfizer, Roche, Tiziana Sciences, GlaxoSmithKline S.p.A, Spectrum Pharmaceuticals, Clovis, Merck Serono, Bayer, Sanofi-Aventis, Blueprint Medicine, Merck KGaA, Ipsen, Exelisis, Otsuka Pharma, Janssen and Spectrum Pharmaceuticals.
